Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Bausch + Lomb makes and sells eye health products, from contact lenses and vitamins to prescription eye medicines and surgical tools.
Bausch + Lomb is an eye health company. It sells the things people put in, on, and around their eyes: contact lenses, eye vitamins, prescription eye medicines, and the surgical equipment eye doctors use during procedures. Its customers are two very different groups — ordinary people buying contact lenses and supplements, and eye care professionals like optometrists and surgeons who choose which products to use in their clinics.
The consumer side is the part most people actually see. The company sells contact lenses under brands like Biotrue and PureVision, plus well-known drops and supplements such as PreserVision eye vitamins and Lumify redness reliever. These are repeat purchases: contact lens wearers buy boxes every month, and vitamin users restock regularly. That steadiness is the appeal — it is less like selling a one-time gadget and more like selling toothpaste. The other half is medical. Bausch + Lomb sells prescription eye drugs, including treatments for dry eye and glaucoma, and it makes surgical devices for cataract and retina operations. This side depends on eye doctors trusting the products and on an aging population needing more eye care. Cataract surgery, in particular, is one of the most common operations in the world, and every one of those procedures uses disposable tools and replacement lenses, which the company supplies.
The business carries real baggage. Bausch + Lomb was spun out of Bausch Health in 2022, and it still carries a heavy debt load from that history. It faces tough competition from much larger players like Alcon and Johnson & Johnson in contact lenses and surgical gear, plus AbbVie in eye drugs. The company spends heavily on research and has been cutting costs to shore up its balance sheet. The simple version: it sells small, repeat-purchase items to millions of people and high-value tools to eye surgeons, and its main job now is turning that steady demand into profits while digging out from under its debt.
Saved answer · last researched 15 Nov 2026